JP7857666B2 - 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 - Google Patents

糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Info

Publication number
JP7857666B2
JP7857666B2 JP2022563827A JP2022563827A JP7857666B2 JP 7857666 B2 JP7857666 B2 JP 7857666B2 JP 2022563827 A JP2022563827 A JP 2022563827A JP 2022563827 A JP2022563827 A JP 2022563827A JP 7857666 B2 JP7857666 B2 JP 7857666B2
Authority
JP
Japan
Prior art keywords
hgf
dose
administration
promoter
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563827A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022107853A1 (cg-RX-API-DMAC7.html
JPWO2022107853A5 (cg-RX-API-DMAC7.html
Inventor
健一郎 小戝
恵理子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagoshima University
Original Assignee
Kagoshima University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagoshima University filed Critical Kagoshima University
Publication of JPWO2022107853A1 publication Critical patent/JPWO2022107853A1/ja
Publication of JPWO2022107853A5 publication Critical patent/JPWO2022107853A5/ja
Application granted granted Critical
Publication of JP7857666B2 publication Critical patent/JP7857666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022563827A 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 Active JP7857666B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020192844 2020-11-19
JP2020192844 2020-11-19
JP2021145795 2021-09-07
JP2021145795 2021-09-07
PCT/JP2021/042463 WO2022107853A1 (ja) 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Publications (3)

Publication Number Publication Date
JPWO2022107853A1 JPWO2022107853A1 (cg-RX-API-DMAC7.html) 2022-05-27
JPWO2022107853A5 JPWO2022107853A5 (cg-RX-API-DMAC7.html) 2023-10-24
JP7857666B2 true JP7857666B2 (ja) 2026-05-13

Family

ID=81707991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563827A Active JP7857666B2 (ja) 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Country Status (4)

Country Link
US (1) US20230414718A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249003A4 (cg-RX-API-DMAC7.html)
JP (1) JP7857666B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022107853A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP7040806B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Circulation,2003年,Vol. 107, No. 19,p. 2499-2506
EXPERIMENTAL and MOLECULAR MEDICINE,2003年,Vol. 35, No. 6,p. 494-500
Gene,1991年,Vol. 108, No. 2,p. 193-200
Korean J Physiol Pharmacol,2003年,Vol. 7,p. 261-266
Life Sciences,2021年03月,Vol. 268, No. 119014,p. 1-5
Nephron Physiology,2006年,Vol. 102,p. 92-102
ウイルス,2003年,Vol. 53, No. 2,p. 147-153

Also Published As

Publication number Publication date
WO2022107853A1 (ja) 2022-05-27
JPWO2022107853A1 (cg-RX-API-DMAC7.html) 2022-05-27
EP4249003A4 (en) 2024-10-23
US20230414718A1 (en) 2023-12-28
EP4249003A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
US11975078B2 (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
JP2023144087A (ja) 組換えGlut1アデノ随伴ウイルスベクターコンストラクトおよびGlut1発現を回復させる方法
JP2025063034A (ja) ライソゾーム病の遺伝子治療
JP2004500880A (ja) 肝臓特異的な遺伝子発現カセット、及びその使用法
KR20220107243A (ko) Apoe 유전자 요법
CN104936606A (zh) 糖原贮积病的基因疗法
US6410011B1 (en) Gene therapy for restenosis using an adenoviral vector
JP7287611B2 (ja) 改良型アデノ随伴ウイルスベクター
KR20160137908A (ko) 당뇨병-연관 심기능 장애 및 울혈성 심부전을 치료하기 위한 우로코르틴-2 및 연관 유전자들을 인코딩하는 바이러스 벡터들의 전신 전달
JP2022511227A (ja) Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療
US20240173381A1 (en) Hb-egf gene therapy for diabetes
US20100184838A1 (en) Compositions and methods for retinal transduction and photoreceptor specific transgene expression
US20160144055A1 (en) Gene therapy vector for treatment of steroid glaucoma
US20230414718A1 (en) Low-dose hepatocyte growth factor gene therapy for diabetes
HK40095489A (en) Low-dose hepatocyte growth factor gene therapy for diabetes
RU2853169C2 (ru) Генотерапия с использованием hb-egf для лечения диабета
CN116685340A (zh) 针对糖尿病的低剂量的肝细胞生长因子基因治疗
HK40103669A (en) Hb-egf gene therapy for diabetes
US20230101788A1 (en) Gene therapy
CN117279670A (zh) 用于糖尿病的hb-egf基因治疗
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US20260041794A1 (en) Expression cassette for target gene and use thereof
US12281323B2 (en) Treatment for restoring ureagenesis in carbamoyl phosphate synthetase 1 deficiency
HK40104471A (en) Expression cassettes for target genes and their applications
TW202521698A (zh) 用於目標基因的表現匣及其應用

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20230407

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260420

R150 Certificate of patent or registration of utility model

Ref document number: 7857666

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150